NPF Fellows Symposium

Article

We are pleased to open the application period for our annual Fellows Symposium.

We are pleased to open the application period for our annual Fellows Symposium.

CME credits and travel scholarships are available to physicians and PhD-level scientists who have demonstrated an interest in pancreatic disease.

The application and other information is available here: http://pancreasfoundation.org/pancreas-community/medical-community/fellows-symposium/

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Subscribe Now!
Recent Videos
Image of a woman wearing a patterned shirt in front of a dark blue background
Photo of a woman wearing a blazer in front of an Oncology Nursing News backdrop
3 experts in this video
3 experts in this video
Photo of a white man with curly hair and in front of a blue Oncology Nursing News backdrop
Related Content
Image of a person holding a model of the female reproductive system

Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

Gina Mauro
June 13th 2025
Article

Relacorilant plus nab-paclitaxel improved PFS and showed a trend toward longer OS in platinum-resistant ovarian cancer in ROSELLA.

The Vitals

What New Cancer Drugs Were Approved in 2023?

Lindsay Fischer
January 1st 2024
Podcast

In this special episode of The Vitals, we ring in the New Year 2024 by combing through 2023 FDA approvals.

Graphic that resembles a stamp of approval reading "FDA Approved"

FDA Approves Perioperative Pembrolizumab in Head and Neck SCC

Bridget Hoyt
June 12th 2025
Article

The FDA approved a perioperative pembrolizumab regimen in head and neck squamous cell carcinoma, marking the first approval in this cancer type in 6 years.

The Vitals

Finley-Oliver Talks Talquetamab and Other Later Line Multiple Myeloma Therapies

Lindsay Fischer
December 14th 2023
Podcast

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

Photo of the FDA building

FDA Approves Mitomycin Intravesical Solution in Low-Grade NMIBC

Bridget Hoyt
June 12th 2025
Article

UGN-102 has received FDA approval for use in patients with low-grade intermediate-risk non-muscle-invasive bladder cancer.

Anatomical image of a person with the gastrointestinal tract highlighted

Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

Jordyn Sava
June 12th 2025
Article

Lasting survival benefits vs chemotherapy or monotherapy were achieved with nivolumab and ipilimumab for patients MSI-H/ dMMR metastatic colorectal cancer.